Ascletis’ ASC30 Shows 1.7% Placebo-Adjusted HbA1c Reduction in Phase II
Ascletis said its oral GLP-1 candidate ASC30 demonstrated a placebo-adjusted HbA1c reduction of 1.7% at 12 weeks in a U.S. Phase II study in participants with diabetes.
Related stories
MGRC Reports Fiscal Q3 Profit and EPS
MGRC reported fiscal 2026 third-quarter profit attributable to shareholders, up 2.84% year over year, and basic EPS.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
ROG Reports Fiscal Q3 Profit Growth of 161.3%
ROG reported fiscal 2026 third-quarter profit attributable to shareholders up 161.3% year over year, with basic EPS also reported.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
PBI Reports Fiscal Q3 Profit and EPS
Profit attributable to shareholders rose 36.94% year over year; basic EPS was also reported.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
Company Reports Fiscal Q3 Attributable Loss
The company reported attributable profit of -7.29亿美元 for fiscal Q3 2026, down 371% year over year.
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
Indonesia central bank governor calls MSCI warning a short-term shock
Destry Damayanti said MSCI’s recent warning about a possible downgrade of Indonesian equities would be only a short-term shock.
L impact | EQUITY | Oct 29, 2026, 09:37 AM UTC
MQ Technology Q2 FY27 Net Loss Widens to RM 8.25 Million
M impact | EQUITY | Oct 29, 2026, 09:37 AM UTC